Skip to main content
Top
Published in: Supportive Care in Cancer 6/2016

01-06-2016 | Original Article

Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy—results from the prospective multi-center study BRENDA II

Authors: Lukas Schwentner, Reyn Van Ewijk, Thorsten Kühn, Felix Flock, Riccardo Felberbaum, Maria Blettner, Rolf Kreienberg, Wolfgang Janni, Achim Wöckel, Susanne Singer

Published in: Supportive Care in Cancer | Issue 6/2016

Login to get access

Abstract

Background

This study examined which patient- and physician-related factors influence guideline violations in adjuvant chemotherapy.

Patients and methods

In a prospective multi-center cohort study, patients with primary breast cancer were sampled consecutively over a period of four years (2009–2012). Patients completed a questionnaire prior to surgery and prior to adjuvant therapy. This questionnaire assessed health-related quality of life (QoL) using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, psychiatric co-morbidity with the Patient Health Questionnaire (PHQ), demographic characteristics (age, education), and the intensity of fear for chemotherapy.
After surgery, a multi-professional team discussed recommendation for adjuvant chemotherapy, and this decision was documented in a database together with the indication for chemotherapy according to the German S3 guideline. This multi-professional team was blinded to that algorithm-based decision. Six months later, it was documented whether the patient had received adjuvant chemotherapy or not.

Results

Altogether, 857 patients were included in the study. In 391 of these patients, the tumor board (TB) decided to recommend chemotherapy. The most important reasons for not recommending chemotherapy were somatic co-morbidity not allowing adjuvant chemotherapy and age >75 years.
Of these 391 patients, 73 (19 %) patients eventually did not receive chemotherapy. Deviations from the initial therapy decision were more frequent in older patients (≥75 years) with poor QoL. If the QoL was good, higher age was not related to deviation. There was some evidence that patients with higher education less frequently received chemotherapy (CT). Furthermore, if patients were very afraid of chemotherapy, deviations from the initial therapy decision were more likely. Co-morbidity and fear of CT were not related to the likelihood of deviating from the initial therapy decision.

Conclusion

Nineteen percent of patients eventually did not receive chemotherapy, despite guideline and TB recommendations. In these patients, this mainly occurred in association with poor QoL in elderly patients >75 years old. In the group with a chemotherapy recommendation, patients’ fear of chemotherapy is another factor preventing patients from undergoing adjuvant chemotherapy.
Literature
2.
go back to reference Van Ewijk R, Schwentner L, Wöckel A, König J, Kreienberg R, Blettner M (2013) Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 287(1):103–10CrossRefPubMed Van Ewijk R, Schwentner L, Wöckel A, König J, Kreienberg R, Blettner M (2013) Trends in patient characteristics, treatment and survival in breast cancer in a non-selected retrospective clinical cohort study of 2,600 patients. Arch Gynecol Obstet 287(1):103–10CrossRefPubMed
3.
go back to reference Van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National evaluation team for breast cancer screening in Netherlands study groups (NETB) (2013) Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49(16):3517–25CrossRefPubMed Van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ, National evaluation team for breast cancer screening in Netherlands study groups (NETB) (2013) Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49(16):3517–25CrossRefPubMed
4.
go back to reference Wo JY, Chen K, Neville BA, Lin NU, Punglia RS (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29(19):2619–27CrossRefPubMedPubMedCentral Wo JY, Chen K, Neville BA, Lin NU, Punglia RS (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29(19):2619–27CrossRefPubMedPubMedCentral
5.
go back to reference Kowalski C, Ferencz J, Brucker SY, Kreienberg R, Wesselmann S. Quality of care in breast cancer centers: results of benchmarking by the German Cancer Society and German Society for Breast Disease. Breast 2014; doi: 10.1016/j.breast.2014.11.014 Kowalski C, Ferencz J, Brucker SY, Kreienberg R, Wesselmann S. Quality of care in breast cancer centers: results of benchmarking by the German Cancer Society and German Society for Breast Disease. Breast 2014; doi: 10.​1016/​j.​breast.​2014.​11.​014
6.
go back to reference Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D et al (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–53CrossRefPubMed Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D et al (2010) Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol 21(4):748–53CrossRefPubMed
7.
go back to reference Schwentner L, Wolters R, Wischnewsky MB, Kreienberg R, Wöckel A (2010) Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast 21(2):171–7CrossRef Schwentner L, Wolters R, Wischnewsky MB, Kreienberg R, Wöckel A (2010) Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast 21(2):171–7CrossRef
8.
go back to reference Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R, Rottscholl R et al (2012) Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study. Breast Cancer Res Treat 132(3):1073–80CrossRefPubMed Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R, Rottscholl R et al (2012) Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study. Breast Cancer Res Treat 132(3):1073–80CrossRefPubMed
9.
go back to reference Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R et al (2013) Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival and is there a role for guideline-adherent adjuvant therapy? A retrospective multi-center cohort study of 8,935 patients. Breast Cancer Res Treat 142(3):579–90CrossRefPubMed Wolters R, Wöckel A, Janni W, Novopashenny I, Ebner F, Kreienberg R et al (2013) Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival and is there a role for guideline-adherent adjuvant therapy? A retrospective multi-center cohort study of 8,935 patients. Breast Cancer Res Treat 142(3):579–90CrossRefPubMed
10.
go back to reference Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R et al (2014) The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol 25(3):628–32CrossRefPubMedPubMedCentral Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R et al (2014) The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol 25(3):628–32CrossRefPubMedPubMedCentral
11.
go back to reference Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clin Oncol 22:3685–93CrossRefPubMed Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G (2004) Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clin Oncol 22:3685–93CrossRefPubMed
12.
go back to reference Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer 13:407CrossRefPubMedPubMedCentral Ziller V, Kyvernitakis I, Knöll D, Storch A, Hars O, Hadji P (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer 13:407CrossRefPubMedPubMedCentral
13.
go back to reference D‘Hoore W, Sicotte C, Tiquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32:382–7PubMed D‘Hoore W, Sicotte C, Tiquin C (1993) Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32:382–7PubMed
14.
go back to reference Löwe B, Spitzer RL, Zipfel S, Herzog W (2002) PHQ-D Gesundheitsfragebogen für Patienten. Pfizer, Manual. Karlsruhe Löwe B, Spitzer RL, Zipfel S, Herzog W (2002) PHQ-D Gesundheitsfragebogen für Patienten. Pfizer, Manual. Karlsruhe
15.
go back to reference Spitzer RL, Williams J, Kroenke K (1999) Prime MD today. Evaluation of metal disorders. Pfizer, New York Spitzer RL, Williams J, Kroenke K (1999) Prime MD today. Evaluation of metal disorders. Pfizer, New York
16.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization For Research And Treatment Of Cancer QLQ-C30—a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–76CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization For Research And Treatment Of Cancer QLQ-C30—a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–76CrossRefPubMed
17.
go back to reference Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. EurJ Cancer 37:1345–51CrossRefPubMed Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. EurJ Cancer 37:1345–51CrossRefPubMed
18.
go back to reference Lerman CE, Brody DS, Caputo GC, Smith DG, Lazaro CG, Wolfson HG (1990) Patients’ perceived involvement in care scale: relationship to attitudes about illness and medical care. J Gen Intern Med 5:29–33CrossRefPubMed Lerman CE, Brody DS, Caputo GC, Smith DG, Lazaro CG, Wolfson HG (1990) Patients’ perceived involvement in care scale: relationship to attitudes about illness and medical care. J Gen Intern Med 5:29–33CrossRefPubMed
19.
go back to reference Scheibler F, Freise D, Pfaff H (2004) Die Einbeziehung von Patienten in die Behandlung—Validierung der deutschen PICS-Skalen. J Publ Health 12:199–209CrossRef Scheibler F, Freise D, Pfaff H (2004) Die Einbeziehung von Patienten in die Behandlung—Validierung der deutschen PICS-Skalen. J Publ Health 12:199–209CrossRef
20.
go back to reference Kreienberg R, Kopp I, Albert U, Bartsch H, Beckmann MW, Berg D, et al. Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. German cancer society 2008 Kreienberg R, Kopp I, Albert U, Bartsch H, Beckmann MW, Berg D, et al. Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. German cancer society 2008
21.
go back to reference Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R et al (2012) A comparison of international breast cancer guidelines—do the national guidelines differ in treatment recommendations? Eur J Cancer 48(1):1–11CrossRefPubMed Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R et al (2012) A comparison of international breast cancer guidelines—do the national guidelines differ in treatment recommendations? Eur J Cancer 48(1):1–11CrossRefPubMed
22.
go back to reference Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–44CrossRefPubMed Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–44CrossRefPubMed
23.
go back to reference Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD et al (2012) Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol 30(31):3800–9CrossRefPubMedPubMedCentral Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD et al (2012) Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol 30(31):3800–9CrossRefPubMedPubMedCentral
24.
go back to reference Barron TI, Cahir C, Sharp L, Bennett K (2013) A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer. Br J Cancer 109:1513–21CrossRefPubMedPubMedCentral Barron TI, Cahir C, Sharp L, Bennett K (2013) A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I–III breast cancer. Br J Cancer 109:1513–21CrossRefPubMedPubMedCentral
25.
go back to reference Harbeck N, Blettner M, Hadji P, Jakisch C, Lück HJ, Windermuth-Kieselbach C et al (2013) Patient’s Anastrozole Compliance to Therapy (PACT) program: baseline data and patient characteristics from a population-based, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormone-sensitive early breast cancer. Breast Care (Basel) 8(2):110–20CrossRef Harbeck N, Blettner M, Hadji P, Jakisch C, Lück HJ, Windermuth-Kieselbach C et al (2013) Patient’s Anastrozole Compliance to Therapy (PACT) program: baseline data and patient characteristics from a population-based, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormone-sensitive early breast cancer. Breast Care (Basel) 8(2):110–20CrossRef
26.
go back to reference Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care 21(1):10–9CrossRef Banning M (2012) Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care 21(1):10–9CrossRef
27.
go back to reference Schouten LJ, Jager JJ, van den Brandt PA (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registrations personnel. Br J Cancer 68(5):974–7CrossRefPubMedPubMedCentral Schouten LJ, Jager JJ, van den Brandt PA (1993) Quality of cancer registry data: a comparison of data provided by clinicians with those of registrations personnel. Br J Cancer 68(5):974–7CrossRefPubMedPubMedCentral
Metadata
Title
Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy—results from the prospective multi-center study BRENDA II
Authors
Lukas Schwentner
Reyn Van Ewijk
Thorsten Kühn
Felix Flock
Riccardo Felberbaum
Maria Blettner
Rolf Kreienberg
Wolfgang Janni
Achim Wöckel
Susanne Singer
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3088-3

Other articles of this Issue 6/2016

Supportive Care in Cancer 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine